Compare Baxter International Inc (BAX) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs General Motors Company — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while General Motors Company trades at $77.19 (market cap $69.31B). The key difference: General Motors Company is far larger — about 6.2× Baxter International Inc's market cap, and General Motors Company pays the higher dividend (0.94%). Which is the better fit depends on your goals.
| BAX | GM | |
|---|---|---|
Market Cap | $11.26B | $69.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.22 | $86.38 |
52-Week Low | $15.80 | $48.89 |
Enterprise Value | $18.93B | $172.65B |
Dividend Yield | 0.92% | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
General Motors (GM) trades at $76.72, down 1.45% on the day, with a bearish technical signal from moving averages. The company shows strong cash flow from operations at $26.87B for 2025 and has beaten earnings estimates for three consecutive quarters. Recent news highlights GM's strategic pivot into energy and domestic manufacturing expansion, supported by a 63% analyst buy rating. Valuation metrics include a P/E of 28 and P/S of 0.4, indicating potential value relative to sales.
GM's outlook is mixed: solid cash generation and analyst optimism (consensus target $102) contrast with declining net margins (1.38% in 2025) and rising debt-to-asset ratios (46.79% in 2024). Risks include competitive pressures and macroeconomic headwinds, but the stock offers upside if margin improvements and energy initiatives materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
